LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Начало・Списък с акции・Pulmatrix Inc

Pulmatrix Inc

Затворен

2.05 9.63

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.58

Максимум

2.08

Ключови измерители
By Trading Economics
Приходи	-51K -928K
EPS	-0.24
Марж на печалбата	-60,266.667
Служители	2
EBITDA	-51K -928K

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.5M 6.9M
Предишно отваряне	-7.58
Предишно затваряне	2.05

Pulmatrix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.03.2026 г., 18:43 ч. UTC

Значими събития в новините

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3.03.2026 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3.03.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3.03.2026 г., 23:44 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3.03.2026 г., 23:25 ч. UTC

Пазарно говорене

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3.03.2026 г., 23:25 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

3.03.2026 г., 22:38 ч. UTC

Значими събития в новините

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3.03.2026 г., 22:16 ч. UTC

Печалби

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3.03.2026 г., 22:09 ч. UTC

Печалби

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3.03.2026 г., 22:06 ч. UTC

Печалби

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3.03.2026 г., 22:05 ч. UTC

Печалби

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3.03.2026 г., 22:03 ч. UTC

Печалби

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Tech, Media & Telecom Roundup: Market Talk

3.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

3.03.2026 г., 21:45 ч. UTC

Значими събития в новините

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3.03.2026 г., 21:37 ч. UTC

Печалби

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3.03.2026 г., 21:26 ч. UTC

Значими събития в новините

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3.03.2026 г., 20:31 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3.03.2026 г., 20:04 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3.03.2026 г., 19:17 ч. UTC

Пазарно говорене

Значими събития в новините

Gold and Silver Drop as Energy Surges -- Market Talk

3.03.2026 г., 18:43 ч. UTC

Печалби

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3.03.2026 г., 18:29 ч. UTC

Пазарно говорене

Значими събития в новините

Global Energy Roundup: Market Talk

3.03.2026 г., 18:29 ч. UTC

Пазарно говорене

Значими събития в новините

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3.03.2026 г., 18:22 ч. UTC

Значими събития в новините

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3.03.2026 г., 18:22 ч. UTC

Значими събития в новините

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3.03.2026 г., 18:17 ч. UTC

Пазарно говорене

Значими събития в новините

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3.03.2026 г., 18:14 ч. UTC

Печалби

How Long Can Anthropic Play Defense? -- WSJ

3.03.2026 г., 17:41 ч. UTC

Значими събития в новините

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3.03.2026 г., 17:36 ч. UTC

Значими събития в новините

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3.03.2026 г., 17:28 ч. UTC

Придобивния, сливания и поглъщания

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Сравнение с други в отрасъла

Ценова промяна

Pulmatrix Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Pulmatrix Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.